What’s at stake as Beijing beats global peers with first approval of novel therapy

AI Summary

China has become the first country to approve a novel, globally trialled medicine, surpassing the US, Japan, and Europe, marking an important milestone in its growing biopharmaceutical sector. The National Medical Products Administration highlights this approval as a historic breakthrough supporting China's pharmaceutical ambitions.

China’s drug regulator has for the first time approved a novel, globally trialled medicine ahead of authorities in the United States, Japan and Europe, marking a “historic breakthrough” as the country doubles down on biopharmaceuticals as one of its growth engines. The drug was filed for market approval in multiple countries, and “China was the first in the world to approve it”, Xu Xiaoqiang, head of chemical drugs registration at the National Medical Products Administration (NMPA), told state...